Home > Cardiology > ACC 2021 > Prevention and Health Promotion > Evinacumab lowers triglyceride levels in severe hypertriglyceridaemia

Evinacumab lowers triglyceride levels in severe hypertriglyceridaemia

Presented By
Dr Robert Rosenson, Icahn School of Medicine at Mount Sinai, USA
ACC 2021
Evinacumab resulted in a dramatic reduction in fasting triglyceride levels compared with placebo in a small phase 2 study, but treatment response varied by genotype [1]. Severe hypertriglyceridaemia (sHTG), defined as a fasting triglyceride level of ≥500 mg/dL, is a known risk factor for acute pancreatitis. Angiopoietin-like protein 3 (ANGPTL3) helps to regulate plasma lipid levels via the inhibition of lipoprotein lipase (LPL) and endothelial lipase-mediated hydrolysis of triglycerides and phospholipids [2]. A loss-of-function (LOF) variant of the ANGPTL3 gene results in lower levels of blood triglycerides. Evinacumab is a fully human monoclonal antibody inhibitor of ANGPTL3. A phase 2, randomised, placebo-controlled trial (NCT03452228) explored the feasibility of evinacumab as a therapeutic option for sHTG. The trial assigned 51 pati...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on